Trials / Terminated
TerminatedNCT02932345
Gefitinib Long-term Survivor Study
A Study of Clinical and Genomic Analysis on Long-term Survivors of EGFR Mutation Positive Advanced Non-small-cell Lung Cancer Patients With Gefitinib Treatment in China
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 59 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The primary objective is to describe the genomic profile of long-term survivors, especially to find out potential genomic prognosis and/or predictive factors for gefitinib long-term efficacy as compared to rapid PD patients
Conditions
Timeline
- Start date
- 2016-10-31
- Primary completion
- 2017-07-04
- Completion
- 2017-07-04
- First posted
- 2016-10-13
- Last updated
- 2022-03-24
Locations
14 sites across 1 country: China
Source: ClinicalTrials.gov record NCT02932345. Inclusion in this directory is not an endorsement.